<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04622813</url>
  </required_header>
  <id_info>
    <org_study_id>BIO-2020-0375</org_study_id>
    <nct_id>NCT04622813</nct_id>
  </id_info>
  <brief_title>The Effect of Intraoperative Nefopam, Ketoprofen and Paracetamol Combination vs Ketoprofen and Paracetamol Combination on Postoperative Morphine Requirements After Laparoscopic Cholecystectomy: A Randomized, Controlled Trial</brief_title>
  <official_title>The Effect of Intraoperative Nefopam, Ketoprofen and Paracetamol Combination vs Ketoprofen and Paracetamol Combination on Postoperative Morphine Requirements After Laparoscopic Cholecystectomy: A Randomized, Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>American University of Beirut Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>American University of Beirut Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nefopam is a centrally-acting anti-nociceptive compound with supraspinal and spinal sites of&#xD;
      action. It inhibits monoamine reuptake, modulates descending serotoninergic pain, and may&#xD;
      also interact with a dopaminergic pathway. Because its mechanism of action is distinct from&#xD;
      that of other analgesic opioids, nefopam may well have a role in analgesic protocols. The&#xD;
      role of nefopam in multimodal analgesia has been extensively investigated in laparoscopic&#xD;
      cholecystectomy. However, there is general agreement that more studies are needed to&#xD;
      determine the ideal multimodal strategy. No previous study has investigated a combination&#xD;
      regimen of the three most commonly prescribed non-opioid analgesics (NOA) (nefopam,&#xD;
      ketoprofen, and paracetamol) vs ketoprofen and paracetamol combination during&#xD;
      sevoflurane-dexmedetomidine based anesthesia on pain control after laparoscopic&#xD;
      cholecystectomy.&#xD;
&#xD;
      The aim of our study is to compare a combination regimen of three NOA (nefopam, ketoprofen,&#xD;
      and paracetamol) vs ketoprofen and paracetamol combination during sevoflurane-dexmedetomidine&#xD;
      based anesthesia on pain control after laparoscopic cholecystectomy. We will try to&#xD;
      demonstrate the benefit with the addition of a third NOA, which is the nefopam, to the&#xD;
      double-drug regimen including ketoprofen and paracetamol. Our hypothesis is that this&#xD;
      combination regimen of three NOA is associated with less postoperative pain, less opioid&#xD;
      consumption, shorter length of post-anesthesia care unit (PACU) stay, and fewer&#xD;
      opioid-related adverse effects and postoperative complications compared to the double-drug&#xD;
      regimen of ketoprofen and paracetamol.&#xD;
&#xD;
      In this prospective randomized double-blind study, 90 patients aged 18 to 64 years, with&#xD;
      American Society of Anesthesiologists (ASA) physical status I and II, will be randomly&#xD;
      assigned using a computer-generated random number table to one of two treatment groups. Group&#xD;
      A will receive sevoflurane-dexmedetomidine based anesthesia with ketoprofen and paracetamol&#xD;
      for postoperative pain control, and group B will receive sevoflurane-dexmedetomidine based&#xD;
      anesthesia with nefopam, ketoprofen, and paracetamol for postoperative pain control. The&#xD;
      primary outcome measure of this study is total morphine consumption in PACU. Normally&#xD;
      distributed data will be summarized as mean Â± SD and non-normally distributed data will be&#xD;
      summarized as median [interquartile range]. This study would have an impact on our current&#xD;
      practice and may help find out the best multimodal analgesic strategy to control&#xD;
      postoperative pain after laparoscopic cholecystectomy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 8, 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total morphine consumption in the post anesthesia care unit</measure>
    <time_frame>Throughout the patient's stay in the recovery room (average of 30 minutes after the surgery)</time_frame>
    <description>Total morphine doses consumed after the surgery during the post anesthesia care unit stay of the patient</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Cholecystectomy</condition>
  <condition>Pain, Postoperative</condition>
  <condition>Opioid Use</condition>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Multimodal group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nefopam, ketoprofen, paracetamol</intervention_name>
    <description>Patients in this group will receive Nefopam and Ketoprofen in addition to the paracetamol intraoperatively prior to the anticipated end of the surgery</description>
    <arm_group_label>Multimodal group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>saline infusion, ketoprofen, paracetamol</intervention_name>
    <description>Patients in this group will receive one placebo infusion (saline infusion) in addition to the ketoprofen and paracetamol intraoperatively prior to the anticipated end of the surgery</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ASA physical status I-II&#xD;
&#xD;
          -  Age between 18 and 64 years&#xD;
&#xD;
          -  Patients able to give consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  ASA physical status III to V&#xD;
&#xD;
          -  History of chronic pain&#xD;
&#xD;
          -  Use of an opioid analgesic within 12 hours prior to surgery&#xD;
&#xD;
          -  Alcohol or drug abuse&#xD;
&#xD;
          -  Chronic opioid intake&#xD;
&#xD;
          -  Morbid obesity&#xD;
&#xD;
          -  Psychiatric disorder&#xD;
&#xD;
          -  Pregnancy or breast-feeding&#xD;
&#xD;
          -  Intolerance to NSAIDSs&#xD;
&#xD;
          -  Allergy or contraindication to nefopam (acute angle-closure glaucoma, epilepsy,&#xD;
             coronary artery disease, prostate adenoma), to morphine or paracetamol (liver&#xD;
             failure), to ketoprofen (increased risk of bleeding, stomach or intestinal ulcer,&#xD;
             chronic kidney disease) or to dexmedetomidine (uncontrolled hypertension, heart block&#xD;
             greater than first degree, or other clinically significant morbidities)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>American University of Beirut Medical center</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sahar M Siddik-Sayyid, MD</last_name>
      <phone>+961350000</phone>
      <phone_ext>6380</phone_ext>
      <email>ss01@aub.edu.lb</email>
    </contact>
  </location>
  <location_countries>
    <country>Lebanon</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>October 30, 2020</study_first_submitted>
  <study_first_submitted_qc>November 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2020</study_first_posted>
  <last_update_submitted>June 7, 2021</last_update_submitted>
  <last_update_submitted_qc>June 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>American University of Beirut Medical Center</investigator_affiliation>
    <investigator_full_name>Sahar Sayyid</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Ketoprofen</mesh_term>
    <mesh_term>Nefopam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

